ReviewCurrent topics in medicinal chemistry2013
PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
Review in Current topics in medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04509557 ([177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer: Phase I Clinical Trial.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.Current oncology reports · 2025Pooled it
- PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2016Trial
- Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform forInternational journal of molecular sciences · 2026Article
- 3D Bioprinting and Microfluidic-based Devices for Cancer Detection and Drug Treatment: Focus on Prostate Cancer.Current medicinal chemistry · 2026Review
- Performance ofMolecular imaging and radionuclide therapy · 2025Article
- Development and Evaluation of a Vinyl Sulfone-Based Fluorine-18 Labeling Method for Constructing PSMA-targeted Prostate Cancer Imaging Agents.Molecular imaging and biology · 2025Article
- Review
- Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.iRadiology · 2024Article
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason score.European journal of hybrid imaging · 2023Article
- Article
- Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review.Frontiers in oncology · 2023Review
- System-level optimization in spectroscopic photoacoustic imaging of prostate cancer.Photoacoustics · 2022Article
- Synthesis, preclinical evaluation, and first-in-human study of AlEuropean journal of nuclear medicine and molecular imaging · 2022Article
- A Pilot Study of DynamicMolecular imaging and biology · 2022Article
- Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors.Biophysical reviews · 2022Review
- Cold Kit Labeling: The Future ofFrontiers in medicine · 2022Review
- Evaluation ofTranslational oncology · 2022Article
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer (PCa) is the second leading cause of cancer-related death in American men. Positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease, detection of metastatic lesions and, ultimately, for predicting the aggressiveness of disease. Prostate-specific membrane antigen (PSMA) is a well-characterized imaging biomarker of PCa. Because PSMA levels are directly related to androgen independence, metastasis and progression, PSMA could prove an important target for the development of new radiopharmaceuticals for PET. Preclinical data for new PSMA-based radiotracers are discussed and include new (89)Zr- and (64)Cu-labeled anti-PSMA antibodies and antibody fragments, (64)Cu-labeled aptamers, and (11)C-, (18)F-, (68)Ga-, (64)Cu-, and (86)Y-labeled low molecular weight inhibitors of PSMA. Several of these agents, namely (68)Ga- HBED-CC conjugate 15, (18)F-DCFBC 8, and BAY1075553 are particularly promising, each having detected sites of PCa in initial clinical studies. These early clinical results suggest that PET/CT using PSMA-targeted agents, especially with compounds of low molecular weight, will make valuable contributions to the management of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.